Literature DB >> 26930370

Metabolic status of patients with muscular dystrophy in early phase of the disease: In vitro, high resolution NMR spectroscopy based metabolomics analysis of serum.

Niraj Kumar Srivastava1, Sanjay Annarao2, Neeraj Sinha2.   

Abstract

AIMS: Proton Nuclear Magnetic Resonance (NMR) based metabolomics analysis is extensively used to explore the metabolic profiling of biofluids. This approach was used for the analysis of metabolites in serum of patients with major types of muscular dystrophy in early phase of the disease.
MATERIAL AND METHODS: Proton NMR spectroscopy based qualitative (assignment of metabolites) and quantitative (quantification of metabolites) analysis of metabolites in native serum of patients with Duchenne muscular dystrophy (DMD) [n=88; n represent the number], Becker muscular dystrophy (BMD) [n=40], facioscapulohumeral dystrophy (FSHD) [n=22], limb girdle muscular dystrophy (LGMD)-2B [n=35] and myotonic dystrophy (DM) [n=21] as compared to normal subjects [n=50] were performed. KEY
FINDINGS: Quantity of branched chain amino acids was elevated in serum of patients with DMD, BMD, FSHD and DM-1 as compared to normal subjects. Acetate level was elevated in serum of patients with DMD, BMD, FSHD, LGMD-2B and DM-1 as compared to normal subjects. Level of glutamine was reduced in serum of patients with DMD, BMD, LGMD-2B, FSHD and elevated in DM-1 patients as compared to normal subjects. Quantity of tyrosine was increased in serum of BMD patients as compared to normal subjects. There was a reduction in the level of lysine in serum of FSHD, LGMD-2B and DM-1 patients as compared to normal subjects. Citrate level was reduced in serum of FSHD patients, but elevated in LGMD-2B patients. Lactate level was reduced in serum of LGMD-2B patients and histidine was reduced in serum of patients with FSHD as compared to normal subjects. SIGNIFICANCE: Outcome of this study may be useful as supportive information for the existing diagnostic methods of the muscular dystrophy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMD; Blood; DM; DMD; FSHD; LGMD; Metabolites; Muscular dystrophy; Serum

Mesh:

Substances:

Year:  2016        PMID: 26930370     DOI: 10.1016/j.lfs.2016.01.032

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models.

Authors:  Roula Tsonaka; Mirko Signorelli; Ekrem Sabir; Alexandre Seyer; Kristina Hettne; Annemieke Aartsma-Rus; Pietro Spitali
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

2.  Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy.

Authors:  Pietro Spitali; Kristina Hettne; Roula Tsonaka; Ekrem Sabir; Alexandre Seyer; Jesse B A Hemerik; Jelle J Goeman; Esther Picillo; Manuela Ergoli; Luisa Politano; Annemieke Aartsma-Rus
Journal:  J Cell Mol Med       Date:  2018-02-14       Impact factor: 5.310

Review 3.  Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies.

Authors:  Jorge Espinosa-Espinosa; Anchel González-Barriga; Arturo López-Castel; Rubén Artero
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

4.  Metabolomics diagnostic approach to mustard airway diseases: a preliminary study.

Authors:  BiBi Fatemeh Nobakht Mothlagh Ghoochani; Rasoul Aliannejad; Afsaneh Arefi Oskouie; Mostafa Rezaei-Tavirani; Shiva Kalantari; Mohammad Taghi Naseri; Alireza Akbarzadeh Baghban; Hadi Parastar; Ghazaleh Aliakbarzadeh
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.